Davis Polk advised the joint book-running managers on an SEC-registered offering by Celgene Corporation of $8.0 billion aggregate principal amount of notes. The notes were issued in five tranches: $1.0 billion aggregate principal amount of 2.125% senior notes due 2018, $1.5 billion aggregate principal amount of 2.875% senior notes due 2020, $1.0 billion aggregate principal amount of 3.550% senior notes due 2022, $2.5 billion aggregate principal amount of 3.875% senior notes due 2025 and $2.0 billion aggregate principal amount of 5.000% senior notes due 2045. Celgene intends to use a portion of the net proceeds from the offering to help finance its acquisition of Receptos, Inc.   

Headquartered in Summit, New Jersey, Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory-related diseases.   

The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Christopher M. Bezeg and Alice Z. Chen. Partner Frank J. Azzopardi provided intellectual property tax. The tax team included partner Neil Barr and associate Caitlin Piper. All members of the Davis Polk team are based in the New York office.  

 

Copy link to share post